Novo Nordisk A/S Class B Accounts Payable

Novo Nordisk A/S Class B (NONOF) currently reports a accounts payable of $130B as of March 2026. That compares with $20B in the prior-year period — up 584.8% year over year. Use the charts on this page to explore Novo Nordisk A/S Class B's accounts payable history and peer comparisons.

Novo Nordisk A/S Class B's accounts payable increased from $20B to $130B — a 584.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Novo Nordisk A/S Class B reported $130B in accounts payable as of March 2026. That compares with $20B in the prior-year period — up 584.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $130B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Novo Nordisk A/S Class B, and consider following NONOF for alerts when major investors trade the stock.

Novo Nordisk A/S Class B is classified in the Healthcare sector. On accounts payable, it currently shows $130B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NONOF with unrelated industries.